Background
Phase III RCT (GHSG HD10). 1,370 patients with early favorable Hodgkin lymphoma (stage I–II, no risk factors). 2×2 factorial design testing whether chemotherapy could be reduced from 4 to 2 cycles ABVD, and whether RT dose could be reduced from 30 to 20 Gy. Landmark trial defining minimum effective treatment for early favorable HL. Median follow-up 79 months.
Interventions and follow up
Arm A: ABVD × 4 cycles + IFRT 30 Gy (n=339)
Arm B: ABVD × 4 cycles + IFRT 20 Gy (n=347)
Arm C: ABVD × 2 cycles + IFRT 30 Gy (n=342)
Arm D: ABVD × 2 cycles + IFRT 20 Gy (n=342)
Primary endpoint: Freedom from treatment failure (FFTF)
mFollow up: 79 month
Arm B: ABVD × 4 cycles + IFRT 20 Gy (n=347)
Arm C: ABVD × 2 cycles + IFRT 30 Gy (n=342)
Arm D: ABVD × 2 cycles + IFRT 20 Gy (n=342)
Primary endpoint: Freedom from treatment failure (FFTF)
mFollow up: 79 month
Results
FFTF at 5 years: 93.0% (2 cyc + 20 Gy) vs 93.4% (4 cyc + 20 Gy) vs 93.5% (2 cyc + 30 Gy) vs 96.6% (4 cyc + 30 Gy)
Non-inferiority confirmed: 2 cycles ABVD + 20 Gy IFRT non-inferior to 4 cycles + 30 Gy (P=.39 for superiority)
OS at 5 years: 97.1% (2 cyc + 20 Gy) vs 97.3% (4 cyc + 30 Gy)
Grade 3–4 toxicity: Lower in 2-cycle arms
Non-inferiority confirmed: 2 cycles ABVD + 20 Gy IFRT non-inferior to 4 cycles + 30 Gy (P=.39 for superiority)
OS at 5 years: 97.1% (2 cyc + 20 Gy) vs 97.3% (4 cyc + 30 Gy)
Grade 3–4 toxicity: Lower in 2-cycle arms
Adverse events
Main adverse events: Grade 3–4 toxicity significantly less with 2 cycles vs 4 cycles ABVD: leukopenia 7.4% vs 16.1%. Pulmonary toxicity (bleomycin) lower with 2 cycles. Grade ≥3 toxicity with 20 Gy similar to 30 Gy. No increase in secondary malignancies at this follow-up.
Conclusions
2 cycles of ABVD + 20 Gy IFRT is non-inferior to 4 cycles + 30 Gy for early favorable Hodgkin lymphoma with significantly less acute toxicity. This regimen became the international standard for early favorable HL treatment.
Key Limitations
Key Limitations: Patients selected for 'favorable' criteria (no risk factors) limit generalizability to unfavorable early-stage HL. RT technique evolved to ISRT (involved-site RT) after this trial. Long-term data (HD10 Update, Sasse JCO 2017) confirm maintained efficacy at 12 years with second malignancy surveillance ongoing. RT omission in PET-negative patients (RAPID, EORTC H10) remains an active area.
Clinical Context
HD10 established 2 cycles ABVD + 20 Gy IFRT as the standard of care for early favorable HL. This regimen is incorporated into NCCN, EAU, and ESMO guidelines. The evolution toward PET-guided RT omission (RAPID, H10) is being studied but has not replaced CMT as the standard for PET-negative disease in all guidelines.
References
References: Engert A et al, NEJM 2010 (GHSG HD10)